REG - ConvaTec Group PLC - Scrip Dividend - Calculation Price

ConvaTecAnnouncement

12/04/2021 15:15

RNS Number : 1878V
  
ConvaTec Group PLC
  
12 April 2021
  
 

Scrip Dividend - calculation price
 
 
Reading, United Kingdom (12 April 2021)
On 4 March 2021, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") proposed a final dividend of 3.983 cents per share ("Final Dividend"), subject to approval at the forthcoming Annual General Meeting on 7 May 2021. This Final Dividend is to be paid on 13 May 2021 to shareholders on the share register as at 6 April 2021 ("Record Date"). The Final Dividend is payable in cash, in sterling to holders of ordinary shares, the chosen exchange rate for this payment is $1.400/£1.00, determined on 4 March 2021, giving a total sterling dividend of £57,023,676. A scrip dividend will be made available for this Final Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares.
The "Calculation Price" for the issue of new ordinary shares under the scrip dividend scheme is:
197.00 pence for each new ordinary share.
This is equivalent to 1 new share for approximately 69.24 shares held prior to the ex-dividend date of 1 April 2021.
The Calculation Price is the average of the middle market quotations of a ConvaTec share, derived from the London Stock Exchange Daily Official List, for the five consecutive business days from 1 April to 9 April 2021 (inclusive). 
The latest date for receipt of elections to participate in the scrip dividend scheme for the Final Dividend is 22 April 2021. Shareholders must return their mandate form by 5pm (BST) or otherwise input their CREST elections to be received by the Company's registrar, Computershare, by 3pm (BST) on 22 April 2021. Elections received after this deadline will apply to subsequent dividends only. Unless revoked by you, your scrip dividend election will apply for all future dividends for which a scrip dividend is offered. Evergreen elections for CREST shareholders cannot be accepted and elections will revert to cash by default after the payment of each dividend.
Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the Final Dividend are:




Ex-dividend Date


       1 April 2021


 




Record Date


6 April 2021


 




Scrip calculation price determined


    1-9 April 2021 (inclusive)


 




Scrip calculation price available and announced


                12 April 2021


 




Mandate delivery deadline for Shares held in uncertificated form 


3.00 p.m. on 22 April 2021 


 




Mandate delivery deadline for Shares held in certificated form


5.00 p.m. on 22 April 2021 


 




  Announcement of the total amount of new shares to be issued


                      28 April 2021


 




  Dividend payment date


                       13 May 2021


 




  Dispatch of statement in accordance with section 7 of Scheme


                       13 May 2021 


 




Rules and share certificates, CREST accounts credited/updated, 
and first day of dealings in New Shares
                                                                                                           
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations 
& Corporate Communications                                                   +44 (0)7826 447807
ir@convatec.com
 
Media
Buchanan: Charles Ryland / Chris Lane                                    +44 (0)207 466 5000                                                                                                  
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
 
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com.
 
 
 
# # #
END
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCDKBBKQBKDBQD